Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16340760 | 0.94 | SMN1; SMN2 (0.47) | SMN1; SMN2NOTUMSIGMAR1TSHRCHRM2 | |
| SCHEMBL223607 | 0.88 | ALDH1A1 (0.48) | SMN1; SMN2NOTUMSIGMAR1ALDH1A1MAPT | |
| SCHEMBL7954287 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2NOTUMSIGMAR1ALDH1A1HTT | |
| SCHEMBL3692340 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2NOTUMSIGMAR1ALDH1A1HTT | |
| SCHEMBL30486081 | 0.75 | SMN1; SMN2 (0.55) | SMN1; SMN2NOTUMSIGMAR1ALDH1A1HTT | |
| SCHEMBL1177123 | 0.75 | ALDH1A1 (0.58) | NOTUMALDH1A1HTTMAPTHPGD | |
| SCHEMBL2827646 | 0.73 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1MEN1KMT2ACHRM2 | |
| SCHEMBL10441142 | 0.73 | SMN1; SMN2 (0.49) | SMN1; SMN2NOTUMSIGMAR1ALDH1A1HTT | |
| SCHEMBL1177380 | 0.72 | HSD17B10 (0.58) | NOTUMMEN1KMT2ATSHR | |
| Water SCHEMBL27508232 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2NOTUMSIGMAR1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560450-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2009-07-14 | — | — | US | claimed |
| JP-2006508969-A | — | — | 2006-03-16 | — | — | JP | claimed |
| EP-1565468-A1 | NOVEL XANTHIN DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-08-24 | — | — | EP | claimed |
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| WO-2004046148-A1 | NOVEL XANTHIN DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-03 | — | — | WO | claimed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | claimed |
| JP-2002539201-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | claimed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| EP-0158954-A2 | Tetrahydroquinolin-1-yl carbonyl imidazole derivatives, their intermediates; process for their preparation and herbicides or fungicides for agriculture or horticulture | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1985-10-23 | — | — | EP | claimed |
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8168634-B2 | Thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-05-01 | — | — | US | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| EP-0173208-A1 | Tetrahydroquinolin-1-yl-carbonyl-imidazole derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0173208-A1 | Tetrahydroquinolin-1-yl-carbonyl-imidazole derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0158954-A2 | Tetrahydroquinolin-1-yl carbonyl imidazole derivatives, their intermediates; process for their preparation and herbicides or fungicides for agriculture or horticulture | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1985-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | SMN1; SMN2 2204/4885NOTUM 976/4885SIGMAR1 1545/4885 |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | SMN1; SMN2 4034/4885NOTUM 574/4885SIGMAR1 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.